RedHill Biopharma (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting specialty gastrointestinal drugs in the U.S., including RedHill’s recently FDA approved drug, Talicia® for H. pylori infection and Movantik for OIC. RedHill’s pipeline includes several drug candidates in advanced stages of clinical development, including an ongoing global Phase 2/3 development program for COVID-19, a planned pivotal Phase 3 study for pulmonary NTM infections and additional Phase 2 and Phase 3 development programs.
Ticker:
RDHL
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Israel
Year Founded:
2009
Main Therapeutic Focus:
COVID-19
Lead Product in Development:
Talicia
Development Phase of Primary Product:
Multiple Products in Market
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
